Northfield Files BLA For Blood Substitute, Seeks Capital Infusion
Executive Summary
Northfield Laboratories hopes to translate enthusiasm on Wall Street for the first BLA submission for a blood substitute into at least $40 mil. of additional capital to help commercialize PolyHeme.